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The Charcot-Marie-Tooth (CMT) disorders comprise a group of clinically and genetically heterogeneous hereditary
motor and sensory neuropathies, which are mainly characterized by muscle weakness and wasting, foot deformities,
and electrophysiological, as well as histological, changes. A subtype, CMT2, is defined by a slight or absent reduction
of nerve-conduction velocities together with the loss of large myelinated fibers and axonal degeneration. CMT2
phenotypes are also characterized by a large genetic heterogeneity, although only two genes—NF-L andKIF1Bb—have
been identified to date. Homozygosity mapping in inbred Algerian families with autosomal recessive CMT2 (AR-
CMT2) provided evidence of linkage to chromosome 1q21.2-q21.3 in two families ( ). All patients sharedZ p 4.14max
a common homozygous ancestral haplotype that was suggestive of a founder mutation as the cause of the phenotype.
A unique homozygous mutation in LMNA (which encodes lamin A/C, a component of the nuclear envelope) was
identified in all affected members and in additional patients with CMT2 from a third, unrelated family. Ultrastructural
exploration of sciatic nerves of LMNA null (i.e., 5/5) mice was performed and revealed a strong reduction of axon
density, axonal enlargement, and the presence of nonmyelinated axons, all of which were highly similar to the
phenotypes of human peripheral axonopathies. The finding of site-specific amino acid substitutions in limb-girdle
muscular dystrophy type 1B, autosomal dominant Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy type
1A, autosomal dominant partial lipodystrophy, and, now, AR-CMT2 suggests the existence of distinct functional
domains in lamin A/C that are essential for the maintenance and integrity of different cell lineages. To our knowledge,
this report constitutes the first evidence of the recessive inheritance of a mutation that causes CMT2; additionally,
we suggest that mutations in LMNA may also be the cause of the genetically overlapping disorder CMT2B1.
Introduction
The Charcot-Marie-Tooth (CMT) disorders, also known
as “hereditary motor and sensory neuropathies”(HMSNs),
comprise the most common group of inherited neurop-
athies, affecting 10–40/100,000 individuals. A clinical,
neuropathologic, electrophysiological, and genetic het-
erogeneity characterizes the CMT disorders (Skre 1974).
Schematically, on the basis of nerve-conduction veloci-
ties (NCVs) at the median nerve, the CMT disorders can
be divided into two main subtypes—demyelinating (i.e.,
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type 1, or CMT1) and axonal (i.e., type 2, or CMT2)
neuropathies, showing NCVs !38 m/s and 138 m/s, re-
spectively (Garcia 1999).
Genetically, CMT2 is a heterogeneous group of pe-
ripheral neuropathies, and, in contrast to CMT1, for
which seven genes and 30 loci have been reported
thus far (for review, see Reilly 2000), very little is
known concerning their genetic bases. To date, only
two specific genes responsible for autosomal dominant
CMT2 (AD-CMT2) have been identified. Mutations
in the neurofilament-light (NF-L) gene, which encodes
a member of the intermediate filaments (IF) family of
proteins, cause CMT2E (MIM 162280) (Mersiyanova
et al. 2000), and mutations in KIF1Bb, which encodes
a microtubule motor protein that is a member of the
kinesin superfamily of proteins, have recently been
demonstrated to cause CMT2A (MIM 118210) (Zhao
et al. 2001). Besides these mutations, gene defects in
MPZ, which encodes myelin protein zero, which were
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initially reported to cause CMT1B (MIM 118200),
Dejerine-Sottas disease (MIM 145900), and congen-
ital hypomyelination (MIM 605253), also cause ax-
onal phenotypes (Marrosu et al. 1998; Chapon et al.
1999; Misu et al. 2000).
Conversely, no genes responsible for autosomal re-
cessive CMT2 (AR-CMT2) have yet been identified, al-
though three loci have been localized on chromosomes
1q21.2-q21.3 (for CMT2B1 [MIM 605588]) (Bou-
houche et al. 1999), 19q13.3 (for CMT2B2 [MIM
605589]) (Leal et al. 2001), and 8q21.3 (Barhoumi et
al. 2001). AR-CMT2 is a rare and severe condition (De
Jonghe et al. 1998; Gemignani et al. 2001).
Clinically, the main symptoms in 90% of cases are
early onset, symmetrical muscle weakness and wasting
(predominantly in the distal lower limbs), foot defor-
mities, and walking difficulties associated with reduced
or absent tendon reflexes (De Jonghe et al. 1998; Gem-
ignani et al. 2001). Confirmation of diagnosis relies
essentially on electrophysiology, which shows NCVs
138 m/s at the median nerve, and on histopathology
after nerve biopsy, which evidences a loss of myelin-
ated fibers with (for AD-CMT2) or without (for AR-
CMT2) regenerative attempts (De Jonghe et al. 1998;
Gemignani et al. 2001).
In the present study, we report a homozygous
892CrT mutation in exon 5 of LMNA, which encodes
lamin A/C nuclear-envelope proteins. This mutation,
causing an R298C amino acid substitution, segregates
as a disease-causing founder mutation in individuals
with AR-CMT2 from three Algerian families in which
the disease was linked to chromosome 1q21.2-q21.3.
Furthermore, the phenotype of Lmna knockout mice
(Sullivan et al. 1999), as determined by analysis of pe-
ripheral nerves, was examined. Ultrastructural analysis
of sciatic nerves of Lmna null (i.e., /) mice revealed
neuropathic features—a strong reduction of axon den-
sity that was accompanied by an increase in axon di-
ameter and the presence of nonmyelinated axons—that
were highly similar to those found in human peripheral
axonopathies.
Since LMNA mutations have been associated with
limb-girdle muscular dystrophy type 1B (LGMD1B
[MIM 159001]) (Muchir et al. 2000), autosomal dom-
inant Emery-Dreifuss muscular dystrophy (AD-EDMD
[MIM 181350]) (Bonne et al. 1999), dilated cardiomyop-
athy type 1A (CMD1A [MIM 115200]) (Fatkin et al.
1999), and autosomal dominant partial lipodystrophy
(PLD [MIM 151660]) (Shackleton 2000), the specific as-
sociation between the R298C amino acid substitution
and AR-CMT2 suggests the existence of distinct func-
tional domains in lamin A/C that are essential for the
maintenance and integrity of different cell lineages. To
our knowledge, the present article constitutes the first
evidence of a mutation that causes CMT2 to be inherited
as a recessive trait and, additionally, suggests that LMNA
mutations may be the cause of the genetically overlapping
disorder CMT2B1 (also called “AR-CMT2A”) (Bou-
houche et al. 1999).
Subjects and Methods
Families and Phenotype Analysis
Twenty-three consanguineous families originating
from Algeria were examined in the Services de Neurol-
ogie, Centre Hospitalier Universitaire Ben-Aknoun and
Centre Hospitalier Universitaire Mustapha, Algiers, Al-
geria. Detailed clinical and electrophysiological exami-
nations were performed, and inclusion criteria were
those of axonal neuropathy, as described elsewhere (De
Jonghe et al. 1998; Gemignani et al. 2001). Informed
consent, for both blood collection and nerve biopsy, was
obtained from all individuals participating in this study.
This study complies with the ethical guidelines of the
institutions involved.
Histology
Nerve biopsies were performed on the external branch
of the musculocutaneous nerve in the foot of human
subjects, and the samples were prepared for electron mi-
croscopy, as described elsewhere (Hahn et al. 2001). Sci-
atic nerves from mice were fixed in 2.5% glutaraldehyde,
were dehydrated, were embedded in paraffin, and were
sectioned before being stained in hematoxylin and eosin.
Genotyping
Genomic DNA was extracted from peripheral-
blood lymphocytes by standard procedures. Genotyp-
ing experiments were performed using polymorphic
microsatellite DNA markers that were retrieved from
the Ge´ne´thon genetic map. The following microsatel-
lite markers were used to test linkage with chromo-
some 1q21.2-q21.3: D1S498 (AFM336xb1), D1S305
(AFM220xf8), D1S2715 (AFMa357ze5), D1S303
(AFM081zc5), D1S2777 (AFMb337zh1), D1S2721
(AFMb009zb9), D1S2624 (AFMa123wg5), and
D1S2635 (AFMa133ye5). Marker informativity var-
ied from 0.63 to 0.87. PCRs were set in a 30-ml total
reaction volume that contained 0.05–0.1 mg genomic
DNA, 0.2 mg each primer (one of which was 5′ labeled
with IRD-800), 200 mM each dNTP, 3 ml 10# PCR
buffer, and 1 ml Taq polymerase (Promega). After an
initial 3-min cycle at 95C, 30–38 cycles of amplifi-
cation were performed for 30–60 s at 95C, 55–60C,
or 72C, depending on the primer pair; a 7-min elon-
gation step (72C) completed the reactions. PCR prod-
ucts were visualized under UV light after electropho-
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Table 1
PCR Primers for Sequence Analysis of LMNA, A1U, and FLJ12287
GENE AND EXON(S)
PRIMER
(5′r3′)
Forward Reverse
LMNA:
Exon 1 ccgagcagtctctgtccttc ccctctcactcccttcctg
Exon 2 gcactgtctaggcacacagact gggagggcctaggtagaaga
Exon 3 tgtgaccccttttcctcatc cactagggcaagggactcag
Exons 4 and 5 ggcctcccaggaactaattc gtggggacacttttcatccc
Exon 5 (R298C) ctcccagtcaccacagtcct gtggttgtggggacactttt
Exons 6 and 7 cttccccatacttagggccc aaggatgttcctctctccac
Exons 8 and 9 gcaagatacacccaagagcc gctccgatgttggccatcag
Exon 10 gtagacatgctgtacaaccc ggccagcgagtaaagttcca
Exon 11 ttgggcctgagtggtcagtc gacccgcctgcaggatttgg
Exon 12 atcgaggggtaggacgaggt taaggcagatgtggagtttcc
A1U:
Exon 1 agttctgggggttcctgttc cccatctcttcgcagacc
Exons 2 and 3 ccacagtgacctctgcctct ccccaaacaagattgtgctc
Exon 4 tcttgtggcagactgtgacc agtgtcctccagctctccag
Exon 5 gttggtgctcccctggtt cactaccctggcccttgat
Exon 6 aacccaaaacctttccctcct gaccccactaagctccttcc
Exon 7 tctggaccctttctctcctg ctctcctcatgctggtttca
Exons 8–10 aggtctccccctgctacct cccccactgcctcatgta
Exon 11 ctgtgcccacttcacaagg gctgcagagggtaaggattg
FJL12287:
Exon 1 cctgccaccaatacacacgc ccacctccagctctctattg
Exon 2 ccacttttatctcaggagtc tattcatgcacaggcagcca
Exon 3 cagctagaactgaggacct tccagggatggtctagggat
Exons 4 and 5 gggtccagcaatttgagtca ccatatttcacagcgtgactg
Exon 6 ccccgagactgatatgatg ggacacattgtaccttccgc
Exons 7 and 8 gttttcactcaggcaaaccc tcatgtcaattcctgcctcc
Exon 9 cttatcaacacagtgagggg gctataccaggtgtaacgtct
Exon 10 aaccaccaccctgaaatgag gggcatcctctgctctagt
Exons 11 and 12 ggaagggatctgtggatgag cagtagcagaagctggctga
Exon 13 cctccttcctcttcccactt gtcttccagagcctttgcacc
Exon 14 gctggggtccaaagataggt tcctagtcagggctgtgctt
resis on a 1.5% agarose gel before genotyping, which
was performed on a Li-Cor 4200 automated sequenc-
ing analyzer as described by Villard et al. (2001).
Linkage Analysis
Statistical analysis were performed assuming autoso-
mal recessive mode of inheritance with full penetrance
and with disease-allele frequency at 0.001, and two-
point LOD scores were calculated using MLINK in the
LINKAGE computer package (Lathrop et al. 1984). For
linkage disequilibrium, allele frequencies in mutant chro-
mosomes were compared to those observed in 100 con-
trol chromosomes from 50 unrelated individuals who
originated from Algeria, and significance was established
using the standard test.2x
Mutation Analysis
The public annotation database at the University of
California–Santa Cruz Human Genome Project Working
Draft (“Golden Path”) was used to integrate genetic,
physical, and transcriptional data on the LMNA region
from D1S2715 to D1S2624. PCR-amplified products cor-
responding to the coding sequences of A1U, FLJ12287,
and LMNA (GenBank accession numbers AF188240,
AK022349, and XM_044163, respectively), including
exon-specific fragments and splice sites (all primers used
in this study are listed in table 1), were purified with the
QIAquick 50 PCR purification kit (Qiagen). M13 uni-
versal (GGTGTAAAACGACGGCCAGT) and reverse
(GGCAGGAAACAGCTATGACC) plasmid sequences
were added to the 5′ end of each forward primer and
reverse primer, respectively. All the PCR products were
further sequenced on both strands by use of either a dye
terminator procedure (PE Biosystems), when sequencing
reactions were loaded on ABI310 automated sequenc-
ing analyzer (Applied Biosystems), or a dye primer pro-
cedure, when sequencing reactions were loaded on Li-
Cor 4200 automated sequencing analyzer (Li-Cor).
All sequencing reactions were performed under condi-
tions recommended by the manufacturers. The LMNA
892CrT mutation was specifically amplified with the
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Figure 1 Ultrastructural micrograph of peripheral nerve from
an individual from family ALG.16-301 who is affected with CMT2.
A severe rarefaction of myelinated and nonmyelinated fibers can be
observed. Large myelinated fibers are almost totally lacking. Neither
onion bulbs (proliferations of Schwann cells) nor regenerating clus-
ters are present. Nerve biopsies were performed, and the samples
were prepared for electron microscopy as described elsewhere (Hahn
et al. 2001).
following primers flanking exon 5: LMNA5-F (5′-CTCC-
CAGTCACCACAGTCCT-3′) and LMNA5-R (5′-GTG-
GTTGTGGGGACACTTTT-3′). PCR products were di-
gested by the restriction endonuclease AciI and were
loaded on 3% agarose electrophoresis gels. Sequence
analysis was performed by comparing wild-type and
patients’ sequences by use of the Sequencher software
(Genecodes).
Lamin A/C functional-domain predictions were ob-
tained using the PROSITE database and the COILS
(version 2) program. Amino acid comparisons were per-
formed using the BLASTP program in the National Cen-
ter for Biotechnology Information database (BLAST).
Results
Clinical and Electrophysiological Findings
We examined 23 Algerian families in which the mode
of inheritance was autosomal recessive and whose af-
fected members presented with severe and early-onset
CMT2. They showed abolished deep-tendon reflexes, as
well as distal amyotrophy, mainly affecting the lower
limbs. Motor deficits were distal in the upper limbs and
both proximal and distal in the lower limbs. A patient’s
gait was thus characterized by marked lifting of the
knees and waddling. Mean  SD motor NCVs mea-
sured at the median nerve were m/s, whereas59 10
sensory potentials were undetectable at sural, cubital,
and median nerves. Ultrastructural analysis of peripheral
nerves revealed a significant loss of large myelinated fi-
bers (984/mm2 vs. 5,640/mm2 in normal controls), as
well as the presence of abnormally myelinated axons (De
Jonghe et al. 1998). Neither proliferations of Schwann
cells (“onion bulbs”) nor regenerating “clusters” were
observed (fig. 1). Further clinical, histological, and elec-
trophysiological features associated with families with
AR-CMT2 will be presented in a future article.
Linkage Study and Linkage Disequilibrium
Genotyping analysis showed significant linkage to
chromosome 1q21.2-q21.3, from D1S305 to D1S2635
( at at D1S2721), in two familiesZ p 4.14 vp 0max
(ALG.16-301 and ALG.16-315). All affected individu-
als in both families were born of consanguineous parents
and were homozygous for each marker within this region.
Additionally, each affected individual shared a 3.2-cM
common haplotype (2-1-1-7-6 at D1S2715, D1S303,
D1S2777, D1S2721, and D1S2624, respectively) in both
of these families (fig. 2). In a third, unrelated family,
which was not included in the linkage analysis because
DNA from only two affected patients was available,
we subsequently observed homozygosity for D1S303,
D1S2777, D1S2721, and D1S2624, possibly indicating
linkage to the same interval. All patients in these three
families shared a smaller homozygous haplotype (1-1-7
at D1S303, D1S2777, and D1S2721, respectively) and
were homozygous for allele 7 at D1S2721, for which
homozygosity is rare (!2%; ) in Algerian pop-P ! .001
ulations. These observations (1) suggested that an an-
cestral haplotype, flanked by D1S2715 and D1S2624,
segregated with AR-CMT2 that was linked to chro-
mosome 1q21.2-q21.3 and (2) were consistent with a
founder effect in families of Algerian descent. Moreover,
we hypothesized that, owing to linkage-disequilibrium
mapping, the disease-causing gene mapped near or at
D1S2721. In the remaining 20 families, linkage to chro-
mosome 1q was clearly excluded, thus confirming the
genetic heterogeneity that is associated with CMT2
disorders.
Sequencing and Mutation Analysis
Flanked by D1S2715 and D1S2624 and encompassing
the linkage-disequilibrium region, an ∼1.5-Mb physical
and transcriptional BAC/PAC contig of sequenced ge-
nomic DNA was thus electronically screened. Among
the numerous potentially transcribed units, including
several characterized human genes, we initially focused
our efforts on the examination of three genes that rep-
resented good candidates owing to their function and
localization—near D1S2721 within the linkage-disequi-
librium region. A1U, which encodes ataxin 1–interact-
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Figure 2 Pedigree of largest Algerian family with AR-CMT2, mutant haplotypes, and integrated map at the LMNA locus. A, Pedigrees
and genotypes of Algerian families ALG.16-301 and ALG.16-315, both with AR-CMT2. Blackened symbols represent subjects with clinical,
electrophysiological, and histological diagnosis of CMT2. The homozygosity interval in each affected individual is boxed and shaded. B,
Genetic, physical, and partial transcriptional map of 1q21.2-q21.3 region. The common haplotype for D1S303, D1S2777, and D1S2721
that is shared by all affected individuals from the three Algerian families is shown (see “Results” section). Position of genetic markers is
indicated with two-point LOD-score values. The positions of A1U, SEMB, and LMNA are indicated.
ing protein, a protein interacting with ataxin (Davidson
et al. 2000), and FLJ12287, a noncharacterized tran-
scribed unit homologous to the mouse Semaphorin B
(SemB) gene (GenBank accession number X85991) (Pu-
schel et al. 1995), were initially analyzed, but sequencing
did not reveal any sequence variation among the pa-
tients. LMNA, which encodes the nuclear-envelope pro-
teins lamin A/C (Moir et al. 2000) and is located 70 kb
proximal to D1S2721 (fig. 2), was then screened for mu-
tations. We sequenced exons and intron-exon junctions
that correspond to the four transcripts (lamin A, AD10,
C, and C2) that were differentially spliced from LMNA
(Furukawa et al. 1994; Machiels et al. 1996), and we
identified a single homozygous CrT mutation in exon 5,
at position 892 of the coding sequence (892CrT). This
mutation resulted in an RrC amino acid substitution at
position 298 (R298C), which was localized in the LMNA
rod domain and thus affected all four transcripts pro-
duced by LMNA (fig. 3). The homozygous 892CrT mu-
tation was present in all affected individuals from the
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Figure 3 Lamin A/C R298C mutation. A, Sequence analysis and identification of R298C mutation in LMNA. DNA sequences from
normal control (/), unaffected heterozygote (/), and homozygote (/) are presented. The RrC amino acid substitution at position
298 of human lamin A/C peptidic sequence is indicated. B, Segregation of the nucleotidic 892CrT mutation in a branch of family ALG.16-
301 assayed by digestion with AciI. The 306-bp PCR product encompassing exon 5 includes one invariant AciI restriction site in wild-type
alleles, which disappears when transition CrT is present, thereby leading to a 306-bp digestion fragment compared with the 126-bp and
180-bp bands observed for the wild-type allele. Normal (n) and mutant (m) fragments, as well as the mutation status (/, /, and /
), are indicated for each individual. Undigested and digested fragment sizes, respectively, are 40 and 20 bp larger than described, owing
to the M13 universal and reverse primers’ sequencing tags (see “Subjects and Methods” section).
three families and cosegregated with the disease in the
two linked families ( at at LMNA, whenZp 5.97 vp 0
we included its mutation as a polymorphic marker in the
pairwise linkage study), whereas the heterozygous carriers
remained clinically asymptomatic regardless of their age
at clinical examination.
Since the 892CrT mutation removed an AciI re-
striction site, the genomic status of each individual was
confirmed after AciI digestion of a specific PCR product
encompassing the complete exon 5 (fig. 3). This test,
applicable as a preliminary 892CrT mutation screen-
ing, was performed in 1300 control chromosomes, in-
cluding 150 from the Algerian population, without the
identification of any mutation. To obtain further evi-
dence that the 892CrT mutation was not a polymor-
phism segregating on a particular Algerian haplotype,
we genotyped 100 Algerian subjects (200 chromo-
somes). We found that six subjects shared the 1-1-7
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Figure 4 Alignment of amino acid sequence of human lamin A/C with its orthologs from various species and human lamin B1, showing
conservation of arginine at position 298. Fully conserved amino acids are shown atop a shaded background. The conservation of arginine
at position 298 and its substitution in patients with AR-CMT2 are shown in boldface. The DNA sequences encoding the normal and mutant
proteins are shown above and below the amino acid sequences, respectively.
haplotype with patients with AR-CMT2 for D1S303,
D1S2777, and D1S2721 on at least one chromosome
without carrying the 892CrT mutation.
Arginine Conservation at Position 298
The lamin A/C amino acid substitution (R298C) that
is associated with the CMT2 phenotype that we here
report lies in the rod domain that is essential for protein-
protein interactions. This domain is highly conserved
through evolution from Caenorhabditis elegans to
Homo sapiens, and the arginine at position 298 is also
conserved in lamin B1 (fig. 4). We predict that the R298C
mutation impairs proteins’ interactions that are essential
for the maintenance of cellular function; calculation of
the consensus value at the PROSITE database by the
COILS (version 2) program revealed a consensus value
for the mutated domain (0.41) that was lower than that
for the wild-type equivalent (1.00).
Axonopathy in Lmna Knockout Mice
Homozygous Lmna knockout mice (Sullivan et al.
1999) display an abnormal gait with a stiff walking pos-
ture, which is characterized by splayed hind legs and the
inability to hang on to structures with their forepaws.
During development, they start to exhibit distinct sco-
liosis/kyphosis and become progressively more hunched.
These aspects are not observed in heterozygous litter-
mates and are extremely evocative of a severe peripheral
neuropathy, since they are also reported in animal mod-
els of peripheral neuropathies (Huxley et al. 1996; Ser-
eda et al. 1996; Norreel et al. 2001).
The responsibility of LMNA homozygous defects for
the impairment of peripheral axons was further analyzed
at the ultrastructural level by the examination of the
sciatic nerves of Lmna knockout mice as compared to
age-matched controls (fig. 5). Whereas heterozygous
(i.e., /) knockout mice showed a preserved periph-
eral-nerve histology, null mice—having lost the full-
length forms of Lmna transcripts (Sullivan et al. 1999)
and showing a strong reduction of axon density, an in-
crease in axon diameter, and the presence of nonmyelin-
ated axons—were histologically similar to human pa-
tients with CMT2.
Discussion
We report linkage to chromosome 1q21.2-q21.3 and
segregation of a specific LMNA 892CrT homozygous
founder mutation in three Algerian families that are af-
fected with AR-CMT2. The R298C amino acid substi-
tution induced by the mutation was determined to have
caused AR-CMT2 in 3 (13%) of 23 inbred Algerian
families and thus is, apparently, a frequent cause of ax-
onal autosomal recessive neuropathies. Additionally, we
report the observation that Lmna null mice present an
axonal pathological phenotype that is highly similar to
that presented by patients with AR-CMT2.
LMNA was regarded as a good candidate in AR-
CMT2 linked to chromosome 1q21, because it had been
mapped to the linkage-disequilibrium region, because
of its expression pattern during neuronal development
(Pierce et al. 1999) and its membership in the IF mul-
tigenic family that also includes NF-L, which is involved
in CMT2E (Mersiyanova et al. 2000; De Jonghe et al.
2001), and because of the wide spectrum of phenotypes
associated with its mutations (Bonne et al. 1999; Fatkin
et al. 1999; Muchir et al. 2000; Shackleton 2000). Ad-
ditionally, the clinical phenotype presented by Lmna
De Sandre-Giovannoli et al.: Gene Defects in LMNA Cause AR-CMT2 733
Figure 5 Electron micrographs from transverse sections of sciatic nerves of Lmna knockout and control mice at age 7 wks. A, Sciatic
nerve of Lmna / control. B, Sciatic nerve of Lmna / mouse. No abnormality was detected, although a slight accumulation of
neurofilaments was observed. Axon density, size, and myelination were preserved. C, Sciatic nerve of Lmna / mouse. Axon density was
reduced, and several pathological axons are indicated by asterisks (*). The axons’ diameters are enlarged, and no myelin sheath is visible;
additionally, they present focal accumulations of neurofilaments, as observed in nerves of Lmna / mouse (bars correspond to 1 mm).
null mice, including locomotor difficulties and kypho-
scoliosis (Sullivan et al. 1999), was thought to be rem-
iniscent of human motor and sensory neuropathies.
These phenotypic features, which were specific to ho-
mozygous knockout mice, were confirmed by the neu-
ropathologic analysis of sciatic nerves, which provided
evidence of an axonopathy with a strong reduction of
axon density, axonal enlargement, and the presence of
nonmyelinated axons, all of which were highly similar
to the phenotypes of human peripheral axonopathies.
It is relevant that these features were not observed in
heterozygous knockout mice, thereby indicating that
loss of function of all lamin A/C proteins is necessary
for the expression of the neuropathic disease, since it
appears to happen in patients who carry the R298C
amino acid substitution.
Although most of the pathogenic mutations previ-
ously reported in LMNA-associated disorders are ex-
pressed when carried by heterozygous individuals, two
patients with EDMD have recently been reported as
being either homozygous or compound heterozygous
for LMNA mutations (Raffaele di Barletta et al. 2000).
In one case, the mutation (H222Y) lies in linker 2 of
the lamin A/C protein, connecting the coiled 1b and
coiled 2a domains; it is interesting that it had been de-
termined that the patient carried either an atypical
EDMD or a congenital muscular dystrophy. At age 40
years, the patient had severe and diffuse muscle wasting
and was confined to a wheelchair, and, moreover, he
showed neither a dilated cardiomyopathy nor any other
cardiac disease; his heterozygous relatives were unaf-
fected (Raffaele di Barletta et al. 2000). In the second
case, the patient carried two different mutations, one
of which (E358K) lies in the coiled 2b domain and the
other of which (R624H) lies in the tail domain (Brown
et al. 2001); muscle weakness was localized proximally
in the upper limbs and distally in the lower limbs, and
the patient did not show any cardiac disease. In patients
with AR-CMT2, the RrC amino acid substitution at
position 298 (R298C) is localized in the lamin A/C rod
domain and thus affects all four known isoforms (A,
AD10, C, and C2) that are produced by LMNA. Ultra-
structural analysis of the peripheral nerves of the pa-
tients whom we studied showed an axonal neuropathic
process; additionally, at clinical examination, patients
presented with a proximal involvement of lower-limb
muscles, whereas no cardiac-conduction disturbances or
dilatation among among patients aged 12–52 years
were observed. These clinical observations are consis-
tent with those reported for the consanguineous Moroc-
can family in which linkage to the 1q21.2-q21.3 region
was first described (Bouhouche et al. 1999).
LMNA mutations have been reported as being as-
sociated with numerous genetic disorders, including
LGMD1B (Muchir et al. 2000), AD-EDMD (Bonne et
al. 1999), CMD1A (Fatkin et al. 1999), and autosomal
dominant PLD (Shackleton et al. 2000). Since LMNA
is ubiquitously expressed, the finding of site-specific
amino acid substitutions in AR-CMT2, as well as in the
disorders described elsewhere, indicates the existence of
distinct functional domains in lamin A/C that are es-
sential for the maintenance and integrity of different
cell lineages. At the same time, much care is needed in
the definition of clinical phenotypes that may share fea-
tures with different disorders. For example, muscle
wasting is observed as a common feature in CMT phe-
notypes and is usually thought to be secondary to nerve
deterioration; that various mutations in a single gene
may lead to neuronal (CMT2) and muscular (CMD1A,
EDMD, and LGMD1B) phenotypes suggests that mus-
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cular phenotypes may be primarily associated with
nerve fibers’ loss or degeneration and should not be
considered only as a delayed consequence of nerve de-
generation. On the basis of these considerations, a closer
examination of the muscular phenotype of patients with
AR-CMT2 and LMNA mutations will be performed.
These considerations may also be correlated with the
recent studies performed on the myotubularin protein
multigene family (Laporte et al. 2001). Mutations in
MTM1 cause myotubular myopathy (Laporte et al.
1996), a severe muscular disorder, whereas mutations
in MTMR2, one of its close homologs, are associated
with CMT4B, a demyelinating motor and sensory neu-
ropathy (Bolino et al. 2000).
The 892CrT mutation has never been reported as
being associated with other phenotypes, and, most
likely, it is a founder mutation that segregates in Al-
gerian families that are affected with AR-CMT2 linked
to the 1q21.2-q21.3 region. Our results add to the ev-
idence of clinical heterogeneity associated with LMNA
mutations that has been described elsewhere and con-
firm that different mutations in this gene may lead to
tissue-specific phenotypes. LMNA thus seems to have a
fundamental function in the regulation of axon devel-
opment and/or survival. These data are supported by
the observation that neuronal LMNA expression seems
to vary in different neuronal subtypes (Cance et al.
1992) and to decrease with the progression of the dif-
ferentiation state (Pierce et al. 1999).
The observation that LMNA mutations cause AR-
CMT2 broadens the range of disorders for which mem-
bers of the nuclear envelope may be considered as can-
didate genes and underscores the role that IFs play in
nerve-fiber survival and regeneration. Besides NF-L and
LMNA, members of the IF family may thus be consid-
ered as candidates for axonal HMSNs. The association
between LMNA mutations and neuronal disorder not
only is being reported for the first time but also signif-
icantly expands our previous views on lamin A/C–as-
sociated pathologies that are restricted to muscle and
lipid tissues. Also, this association greatly advances the
progress made toward comprehension of (1) how mu-
tations in a nuclear structural protein can result in so
many different diseases and (2) how nuclear structure
relates to cellular functions and genetic diseases. Toward
this end, a complete examination of Lmna null mice,
which is specifically focused on peripheral-nerve func-
tion, is being performed. Additionally, a knockin-mouse
line carrying the R298C substitution is being generated
to determine whether this mutation has a specific effect
on peripheral nerves only or affects other tissues. These
mice will also serve as a model to determine how a single
missense mutation impacts protein interactions, since
the founder mutation reported here is predicted to de-
stabilize the lamin interaction domain, and, conse-
quently, nuclear structure and function. The determi-
nation of the function of lamin A/C during the normal
and abnormal development of peripheral nervous sys-
tem and skeletal muscle will shed light on nerve-muscle
interactions, the understanding of which is essential for
the establishment of a comprehensive approach to
HMSNs.
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